Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction -Randomized Controlled Trial of Landiolol vs. Diltiazem-

Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction -Randomized Controlled Trial of Landiolol vs. Diltiazem- - Randomized Controlled Trial of Landiolol vs. Diltiazem

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015053

Enrollment

Registered

2014-09-15

Start date

2014-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure, Atrial Fibrillation/Flutter

Interventions

Landiolol Diltiazem

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The main inclusion criteria were: male or female inpatients aged more than 20 years; New York Heart Association (NYHA) class III or IV; and AF/AFL with an LV ejection fraction (EF) of 25 to 50% and more than 120 beats/min (HR).

Exclusion criteria

Exclusion criteria: The main exclusion criteria were: necessity for electrical cardioversion; serious valve stenosis; confirmed or suspected hyperthyroidism; implantable cardiac pacemaker and/or implantable defibrillator; necessity for mechanical ventilation; and cardiogenic shock (systolic blood pressure (BP) <90 mmHg).

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoint is the percentage of patients with both a HR <110 beats/min and more than 20% decrease from baseline at 2 h after administration. The primary efficacy endpoint is the percentage of patients with severe hypotension, bradycardia.	—

Countries

Japan

Contacts

Public ContactYuichi Kawase

Kurashiki Central Hospital Cardiology

yk13983@kchnet.or.jp086-422-0210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026